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0.4%), and dizziness (2% vs 2%). 3 DB placebo patients (1.1%) discon-
tinued due to AEs during OL. There were no SAEs.
Sildenafil was well tolerated among men with ED who were taking
multiple anti-HTNs. The incidence of AEs was similar in men taking 2
(n307) and 3 (n222) anti-HTNs and consistent with that previously
reported. Less than 2% of patients discontinued because of AEs. Thus,
men who are taking multiple anti-HTNs are not at increased risk for more
frequent or severe AEs while taking sildenafil for ED.
Key Words: Erectile Dysfunction, Controlled Trial, Safety of Sildenafil
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PREVALENCE OF ACE-INHIBITOR USE IN DIABETIC
HYPERTENSIVES IN HYPERTENSION SPECIALITY
CLINIC: A QUALITY ASSURANCE REVIEW
Gregory M. Singer, Munavvar Izhar, William J. Elliott, Henry R.
Black. Preventive Medicine, Rush Medical College, Chicago, IL,
United States.
Renin Angiotensin Aldosterone (RAA) inhibition has been shown to
have beneficial effects in diabetics. We chose to evaluate the usefulness
of drugs that block the RAA Axis including ACE inhibitors (ACEIs) and
the Angiotensin Receptor Blockers (ARBs) in a Hypeternsion Speciality
Clinic.
Charts of 437 Consecutive patients seen at the Rush University Hy-
pertension Center from September, 1998 to February, 2000 were evalu-
ated for blood pressure control and treatment regimen. The Rush Uni-
versity Hypertension Center is comprised of 4 physicians, 3 of whom are
certified Clinical Hypertension Specialists. Physicians based their treat-
ment strategies on current guidelines. No specific clinical pathway was
used and no drug regimen was mandated.
Twenty (20%) of the total patients (N86) were Type II diabetics,
47% were male, there mean age was 61  12 years. The mean blood
pressure upon initial presentation to clinic was 156  24/ 89  12 mm
Hg and was reduced to 137  16/ 78  10 mm Hg after at least one year
of enrolment in the clinic.
ACEIs and ARBs were included in the regimen of 76% diabetic
patients compared to 43% of non-diabetics. Twenty four (24%) of the
diabetics were not treated with ACE inhibitors or Angiotensin Receptor
Blockers. In 9/21 (43%) of the patients the failure to use these drugs was
due to Side effects like cough (4), angioedema (2), hyperkalemia (1),
dizziness (1), and increased creatinine (1). Additionally, physicians
elected non-ACEI/ARB regimens in seven patients with already con-
trolled BP. Four patients refused addition of medications to their current
regimen, and no reason existed for only one patient.
These results indicate that pharmacologic blockade of the RAA Sys-
tem was used in 76% of diabetics, and that contraindication for such
therapy was present in 43% of those who did not recieve it. Quality
assurance surveys should recognize that not all diabetics will recieve
angiotensin antagonists because of existing contraindications and patient
preferences.
Key Words: Standard of Care, Quality Assurance, Angiotensin Blockade
in Diabetics
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EFFICACY OF AN OLMESARTAN MEDOXOMIL-
BASED TREATMENT ALGORITHYM FOR
HYPERTENSION CONTROL IN PRACTICE-BASED
SETTINGS
Joel M. Neutel, David H.G. Smith, Michael A. Weber. Orange County
Heart Institute and Research Center, Orange, CA, United States;
Memorial Research Medical Clinic, Long Beach, CA, United States;
State University of New York Downstate College of Medicine,
Brooklyn, NY, United States.
Introduction: Surveys preformed to assess blood pressure (BP) control
have repeatedly demonstrated worldwide BP control rates of approxi-
mately 25%. In contrast, recent clinical trials have shown that forced-
titration treatment algorithms can help clinicians achieve diastolic BP
goals in the vast majority of patients. Systolic BP goals, however, are
much more difficult to achieve. In this study we sought to establish a
treatment algorithm for a typical clinical setting designed to attain the
increasingly accepted stringent BP control of 130/85 mm Hg in the
majority of patients. The new long-acting angiotensin receptor blocker
(ARB) olmesartan medoxomil was the base therapy and additional agents
were permitted to achieve target BP.
Methods: This open-label, multicenter, forced-titration study enrolled
201 subjects at 17 clinical practice sites. Subjects were characteristic of
hypertensive patients commonly seen in U.S. clinical practice. Mean age
was 53 years; 65% were male; 74% were Caucasian; 16% were African-
American; mean BP was 161.2/96.6 mm Hg. Following wash-out, all
subjects received olmesartan medoxomil 20 mg; if target BP was not
achieved at 4 weeks, olmesartan medoxomil was titrated to 40 mg. In
step-wise manner, hydrochlorothiazide (HCTZ) 12.5 mg to 25 mg and
amlodipine 5 mg to 10 mg were added sequentially beginning at 8 weeks
and every 4 weeks thereafter if BP was not at goal.
Results: With this algorithm, olmesartan medoxomil monotherapy
controlled DBP to90 mm Hg in 80 % of subjects and SBP to140 mm
Hg in 61% of subjects. Using these BP targets, DBP control rates
increased to 91%, 96%, 97%, and 97%, respectively, following the
addition of HCTZ 12.5 to 25 mg and amlodipine 5 to 10 mg. SBP control
rates increased to 78%, 85%, 92% and 94%, respectively, with the
stepped algorithm. Overall, 92% of subjects attained the BP goal of140
and 90 mm Hg with the olmesartan medoxomil-based regimen, and
82% attained the more stringent goal of 130 and 85 mm Hg.
Conclusions: We have demonstrated that when forced by a study
protocol to follow a logical drug algorithm, doctors in a clinical setting
achieved a BP goal of 130/85 mm Hg in more than 80% of subjects
using an olmesartan medoxomil-based regimen.
Key Words: Olmesartan Medoxomil, Hypertension, Blood Pressure
Goals
P-67
DOSE RESPONSE ANTIHYPERTENSIVE EFFICACY
OF ALISKIREN (SPP 100), AN ORALLY ACTIVE
RENIN INHIBITOR
Alice Stanton, John Barton, Chris Jensen, Bobillier Bobillier, Jessica
Mann, Eoin O’Brien. The Blood Pressure Unit, Beaumont Hospital,
Dublin, Ireland; Internal Medicine, Portiuncula Hospital, Ballinasloe,
Ireland; Speedel Pharma AG, Basel, Switzerland.
Aliskiren (SPP 100), an orally active renin inhibitor, has been shown to
inhibit the production of angiotensin I and angiotensin II in healthy
volunteers. In a pilot study, aliskiren decreased BP in hypertensive
patients at daily doses of 75 and 150 mg.
In this multi-centre, double-blind, active comparator trial, the dose-
dependent effects of aliskiren were evaluated in 226 patients with mild to
moderate hypertension. Parallel groups of randomized patients were
assessed at the end of a washout period and again after a 4-week
treatment period. Treatment consisted of single oral daily doses of
MOST FREQUENT AES DURING OL EXTENSION
Adverse Event
(All Causality)
Patients From
DB Sildenafil
(N  259)
n (%)
Patients From
DB Placebo
(N  272)
n (%)
Headache 20 (7.7) 27 (9.9)
Facial flushing 15 (5.8) 17 (6.3)
Dyspepsia 5 (1.9) 8 (2.9)
Dizziness 5 (1.9) 5 (2.2)
Rhinitis 3 (1.2) 6 (2.2)
Abnormal vision 3 (1.2) 7 (2.6)
Chromatopsia 4 (1.5) 4 (1.5)
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aliskiren (37.5, 75, 150 or 300 mg) or of losartan 100 mg once daily.
Daytime ambulatory systolic BP was defined as the primary variable of
the study.
As illustrated in the figure, a clear dose-response curve was observed
for the decrease (mean/- SEM) in daytime ambulatory systolic BP. The
mean (SD) change at the end of the 4-week treatment period was -1.3
(9.5) mmHg, -5.5 (10.6) mmHg, -8.5 (10.4) mmHg, -10.5 (10.7) mmHg,
and -11.1 (13.4) mmHg for 37.5, 75, 150, and 300 mg aliskiren and
100mg losartan, respectively. Statistically significant lowering occurred
with 75, 150 and 300 mg of aliskiren. The daytime ambulatory systolic
BP responses to aliskiren doses of 150 and 300 mg were not significantly
different from that of 100 mg losartan. Similar results were shown for
daytime ambulatory diastolic BP and for night-time ambulatory systolic
and diastolic BP. Aliskiren was well tolerated - there was no increase in
the number of adverse events with increasing doses of aliskiren, and the
safety profile of aliskiren was similar to that of losartan.
The results of this dose-ranging study confirm a dose-dependent re-
duction in BP with aliskiren in mild to moderate hypertension. Additional
exploratory studies testing the efficacy and safety of this new renin
inhibitor in patients with renal disease and congestive heart failure are
currently underway.
Key Words: Renin Inhibitor, Oral Administration, Hypertension
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THE ANTIHYPERTENSIVE EFFICACY AND SAFETY
OF OLMESARTAN MEDOXOMIL COMPARED WITH
AMLODIPINE FOR MILD-TO-MODERATE
HYPERTENSION
Steven G. Chrysant, Thomas Marbury. University of Oklahoma,
Oklahoma City, OK, United States; Orlando Clinical Research Center,
Orlando, FL, United States.
Introduction: This double-blind, randomized, multicenter study was
conducted to compare the efficacy of the newest angiotensin receptor
blocker (ARB), olmesartan medoxomil, with one of the most commonly
prescribed antihypertensive agents, amlodipine, in subjects with mild-to-
moderate hypertension. Olmesartan medoxomil is a new, long-acting,
once-daily ARB that has been shown in a previous study to result in
statistically superior reductions in blood pressure (BP) as compared with
three other ARBs: losartan, valsartan, and irbesartan.
Methods: Following a 4-week placebo run-in period, subjects were
randomized to 8 weeks of therapy with placebo (n66), or the recom-
mended starting doses of amlodipine 5 mg (n186) or olmesartan
medoxomil 20 mg (n188). The primary efficacy variable was the
change from baseline in mean 24-hour diastolic BP as determined by
ambulatory BP monitoring at Week 8. Entry criteria included seated cuff
diastolic BP 100-115 mm Hg and daytime, ambulatory diastolic BP 90
mm Hg. There were no statistically significant differences between
groups at baseline. Mean baseline 24-hour ambulatory BP in the placebo,
amlodipine and olmesartan medoxomil groups was 154/96, 154/95, and
154/96 mm Hg, respectively.
Results: Both active treatments reduced BP at all measures to a
significantly greater degree than did placebo; there were no statistically
significant differences in BP efficacy between amlodipine and olmesartan
medoxomil on any measure. Ambulatory systolic/diastolic BP was re-
duced by 2.3/1.4 on placebo, 12.3/7.0 on amlodipine, and 12.2/7.7 on
olmesartan medoxomil (P0.001 amlodipine and olmesartan medoxomil
vs placebo). Similar findings were reported for cuff BP measurements.
Both agents were equally well-tolerated. The only notable differences in
adverse events were a significantly higher incidence of nausea (2.7%)
with amlodipine as compared with olmesartan medoxomil (0%) or pla-
cebo (0%) (P0.039), and a higher, but not statistically significant,
incidence of edema with amlodipine (9.1%) compared with olmesartan
medoxomil and placebo (4.3%, and 4.5%, respectively.
Conclusions: Olmesartan medoxomil is safe and similarly effective to
amlodipine in subjects with mild-to-moderate hypertension, resulting in
equivalent reductions in both cuff and ambulatory systolic and diastolic BP.
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ATORVASTATIN ASSOCIATED TO VALSARTAN
DOES NOT IMPROVE BLOOD PRESSURE CONTROL
OR PROTEINURIA EXCRETION IN PATIENTS WITH
DIABETIC NEPHROPATHY
Jesus Arteaga, Maria Sorbet, Emma Anda, Manuel Asiron.
Nephrology, Hospital de Navarra, Pamplona, Spain.
In recent years several papers have been published (1) showing that the
use of statins with some antihypertensive drugs could improve the blood
pressure control and could have some synergetic effect(2).
Our proposal had a double Objective: To analyse if atorvastatin is able
to reduce blood pressure and if it is able to decrease proteinuria in a group
of patients with diabetic nephropathy, hypercholesterolemia and hyper-
tension treated with one angiotensin receptor blocker. We included 6
patients (3M,3F), aged (58-71)in treatment with valsartan 160 mg/day as
only antihypertensive drug.
The study was an open, secuential design with each period lasting 3
months. Period A: valsartan 160 mg/day. Period B: valsartan 160mg/day
and atorvastatin 10 mg/day. Period C: valsatan 160 mg/day. We can
detect significant differences in total cholesterol and LDL-cholesterol
between periods with and without atorvastatin (p0,001). There were no
significant differences in blood pressure control, serum creatinine or
proteinuria in 24 hours.
In conclusion, we can not confirm that atorvastatin treatment modifies
systolic or diastolic pressure or has some influence in the progression of
diabetic nephropathy in patients previously treated with valsartan.
(1). Borghi. J. Cardiovasc-Pharmacol 2000;35(4):549-55
(2). Sposito. Am-J-Cardiol 1999;83(10):1497-9
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THE SELECTIVE ALDOSTERONE BLOCKER
EPLERENONE IS SAFE AND EFFICACIOUS FOR THE
LONG-TERM TREATMENT OF MILD-TO-MODERATE
HYPERTENSION
E. Burgess, Y. Lacourciere, A. Puopolo, J. Camplin, B. Roniker, S.
Krause, the plerenone 025 Investigators. University of Calgary,
Calgary, Alberta, Canada; Centre Hospitalier de l’Universite´ Laval,
Ste-Foy, Quebec, Canada; Milford Emergency Associates, Inc.,
Milford, MA, United States; Clinical Research, Inc., Carmichael, CA,
United States; Pharmacia Corporation, Skokie, IL, United States;
Pharmacia Corporation, Skokie, IL, United States.
Eplerenone (EPL), the first selective aldosterone blocker (SAB), binds
preferentially to aldosterone receptors, with little affinity for progesterone
or androgen receptors. EPL is to be used for the treatment of hyperten-
sion and heart failure. This 6- to 16-month, open-label, single-group,
Period A Period B Period C
Systolic 142,27  11,96 141,33  8,75 146  10,53
Diastolic 83,55  5,59 85,72  5,83 88,27  9,50
Total Cholesterol 271,76  28,43 224,16  25,4 267,33  11,21
LDL-Cholesterol 137  12,44 113,16  7,44 135  10
Serum Creatinine 1,3  0,08 1,3  0,1 1,4  0,09
Proteinuria/24 hours 1,50  0,5 1,71  0,47 1,75  0,65
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